Ixempra (ixabepilone) / Otsuka, R-Pharm, BMS, Allarity Therap 
Welcome,         Profile    Billing    Logout  

9 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ixempra (ixabepilone) / Otsuka, R-Pharm, Allarity Therap
NCT00977574: Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

Checkmark ASCO 2015
May 2015 - May 2015: ASCO 2015
Active, not recruiting
2
349
US
Bevacizumab, ABP 215, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, BAT 1706, BAT-1706, BAT1706, BAT1706 Biosimilar, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BAT1706, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-adcd, Bevacizumab-awwb, Bevacizumab-bvzr, BP102, BP102 Biosimilar, CT-P16, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Mvasi, MYL-1402O, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Vegzelma, Zirabev, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Ixabepilone, (1S,3S,7S,10R,11S,12S,16R)-7,11-Dihydroxy-8,8,10,12,16-pentamethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-17-oxa-4-azabicyclo[14.1.0]heptadecane-5,9-dione, Azaepothilone B, BMS 247550, BMS-247550, BMS247550, Epothilone, Epothilone-B BMS 247550, Ixempra, Laboratory Biomarker Analysis, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Temsirolimus, CCI-779, CCI-779 Rapamycin Analog, Cell Cycle Inhibitor 779, Rapamycin Analog, Rapamycin Analog CCI-779, Torisel
National Cancer Institute (NCI), NRG Oncology
Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Recurrent Uterine Corpus Cancer, Stage IIIA Uterine Corpus Cancer AJCC v7, Stage IIIB Uterine Corpus Cancer AJCC v7, Stage IIIC Uterine Corpus Cancer AJCC v7, Stage IVA Uterine Corpus Cancer AJCC v7, Stage IVB Uterine Corpus Cancer AJCC v7
01/15
03/25
2008-000486-29: A feasibility study of dose-dense FEC wiith G-CSF support followed by dose-dense Ixabepilone wiith G-CSF support as neoadjuvant chemotherapy in ER- negative breast cancer

Ongoing
2
48
Europe
IXEMPRA, IXEMPRA
CONSORZIO ONCOTECH
In ER-negative breast cancer
 
 
NCT03093155: Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab

Completed
2
78
US
Ixabepilone, Ixempra, Bevacizumab, Avastin
Yale University, R-Pharm-US, LLC
Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
12/22
12/22
NCT04796324 / 2020-004610-35: Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.

Recruiting
2
60
Europe
Ixabepilone Injection
Allarity Therapeutics, Allarity Therapeutics
Metastatic Breast Cancer
09/24
11/25
NCT00877500: Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy

Active, not recruiting
2
116
US
Best Practice, standard of care, standard therapy, Ixabepilone, (1S,3S,7S,10R,11S,12S,16R)-7,11-Dihydroxy-8,8,10,12,16-pentamethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-17-oxa-4-azabicyclo[14.1.0]heptadecane-5,9-dione, Azaepothilone B, BMS 247550, BMS-247550, BMS247550, Epothilone, Epothilone-B BMS 247550, Ixempra
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Bilateral Breast Carcinoma, HER2/Neu Negative, Invasive Breast Carcinoma
12/24
12/24
ORIENTA, NCT06102824: Organoid-based Functional Precision Therapy for Advanced Breast Cancer

Recruiting
2
252
RoW
Organoid-guided treatment, Taxane, Abraxane, Lipusu, Capecitabine, Xeloda, Gemcitabine, Gemzar, Vinorelbine, Navelbine, Eribulin, Halaven, Anthracycline, Doxil, Lipodox, Carboplatin, Paraplatin, Utidelone, UTD1, Trastuzumab deruxtecan, Enhertu, Sacituzumab govitecan, Trodelvy
Guangdong Provincial People's Hospital, First Affiliated Hospital, Sun Yat-Sen University, Sun Yat-sen University, Shantou Central Hospital
HER2-negative Breast Cancer, Advanced Breast Cancer
06/27
06/28
NCT02344147: Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Active, not recruiting
1
30
US
Ixabepilone, BMS 247550, BMS-247550, Temsirolimus, CCI-779, Torisel, Pharmacological Study, pharmacological studies
Mayo Clinic, National Cancer Institute (NCI)
Adult Solid Neoplasm
06/16
 
NCT01375829: Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Active, not recruiting
1
22
US
Ixabepilone, (1S,3S,7S,10R,11S,12S,16R)-7,11-Dihydroxy-8,8,10,12,16-pentamethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-17-oxa-4-azabicyclo[14.1.0]heptadecane-5,9-dione, Azaepothilone B, BMS 247550, BMS-247550, BMS247550, Epothilone, Epothilone-B BMS 247550, Ixempra, Pharmacological Study, Temsirolimus, CCI-779, CCI-779 Rapamycin Analog, Cell Cycle Inhibitor 779, Rapamycin Analog, Rapamycin Analog CCI-779, Torisel
National Cancer Institute (NCI)
Adult Solid Neoplasm
06/18
03/25
NCT03393741: Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy

Terminated
N/A
5
US
Taxane, paclitaxel, nab-paclitaxel, docetaxel, Vinorelbine, vinca alkaloid, Ixabepilone, epothilone, Eribulin, halichondrins, Chemotherapy
University of Wisconsin, Madison, National Cancer Institute (NCI)
Breast Cancer, Breast Neoplasms
02/24
02/24

Download Options